92 related articles for article (PubMed ID: 9849450)
1. Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.
Marshall E; Howell AH; Powles R; Hunter MG; Edwards M; Wood LM; Czaplewski L; Puttick R; Warrington S; Boyce M; Testa N; Dexter TM; Lord BI; Millar A
Eur J Cancer; 1998 Jun; 34(7):1023-9. PubMed ID: 9849450
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.
Clemons MJ; Marshall E; Dürig J; Watanabe K; Howell A; Miles D; Earl H; Kiernan J; Griffiths A; Towlson K; DeTakats P; Testa NG; Dougal M; Hunter MG; Wood LM; Czaplewski LG; Millar A; Dexter TM; Lord BI
Blood; 1998 Sep; 92(5):1532-40. PubMed ID: 9716580
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.
Bernstein SH; Eaves CJ; Herzig R; Fay J; Lynch J; Phillips GL; Christiansen N; Reece D; Ericson S; Stephan M; Kovalsky M; Hawkins K; Rasmussen H; Devos A; Herzig GP
Br J Haematol; 1997 Dec; 99(4):888-95. PubMed ID: 9432038
[TBL] [Abstract][Full Text] [Related]
4. BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.
Hunter MG; Bawden L; Brotherton D; Craig S; Cribbes S; Czaplewski LG; Dexter TM; Drummond AH; Gearing AH; Heyworth CM; Lord BI; McCourt M; Varley PG; Wood LM; Edwards RM; Lewis PJ
Blood; 1995 Dec; 86(12):4400-8. PubMed ID: 8541527
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide.
Marshall E; Woolford LB; Lord BI
Br J Cancer; 1997; 75(12):1715-20. PubMed ID: 9192972
[TBL] [Abstract][Full Text] [Related]
6. BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation.
Lord BI; Marshall E; Woolford LB; Hunter MG
Br J Cancer; 1996 Oct; 74(7):1017-22. PubMed ID: 8855968
[TBL] [Abstract][Full Text] [Related]
7. Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer.
Broxmeyer HE; Orazi A; Hague NL; Sledge GW; Rasmussen H; Gordon MS
Blood Cells Mol Dis; 1998 Mar; 24(1):14-30. PubMed ID: 9516378
[TBL] [Abstract][Full Text] [Related]
8. The effects of human macrophage inflammatory protein-1 alpha and its genetically modified variant, BB10010, on phagocyte function.
Williams SL; Addison IE; Mollapour E; Czaplewski LG; Linch DC; Roberts PJ
Cytokines Cell Mol Ther; 1997 Mar; 3(1):41-50. PubMed ID: 9287243
[TBL] [Abstract][Full Text] [Related]
9. Macrophage inflammatory protein: its characteristics, biological properties and role in the regulation of haemopoiesis.
Lord BI; Heyworth CM; Woolford LB
Int J Hematol; 1993 Jun; 57(3):197-206. PubMed ID: 8364183
[TBL] [Abstract][Full Text] [Related]
10. Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha.
Cooper S; Mantel C; Broxmeyer HE
Exp Hematol; 1994 Feb; 22(2):186-93. PubMed ID: 8299739
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of BB-10010 treatment on chemotherapy-induced neutropenia in mice.
Gilmore GL; DePasquale DK; Shadduck RK
Exp Hematol; 1999 Feb; 27(2):195-202. PubMed ID: 10029156
[TBL] [Abstract][Full Text] [Related]
12. Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha.
Wark G; Heyworth CM; Spooncer E; Czaplewski L; Francis JM; Dexter TM; Whetton AD
Oncogene; 1998 Mar; 16(10):1319-24. PubMed ID: 9546433
[TBL] [Abstract][Full Text] [Related]
13. Dose-effect relationship of BB-10010/MIP-1 alpha on proliferation in murine small intestinal epithelium: single and double administration protocols.
Arango D; Ettarh RR; Brennan PC
Dig Dis Sci; 2000 Dec; 45(12):2306-12. PubMed ID: 11258549
[TBL] [Abstract][Full Text] [Related]
14. BB-10010, an analogue of macrophage inflammatory protein-1 alpha, reduces proliferation in murine small-intestinal crypts.
Arango D; Ettarh RR; Brennan PC
Scand J Gastroenterol; 1999 Jan; 34(1):68-72. PubMed ID: 10048735
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
[TBL] [Abstract][Full Text] [Related]
16. Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment.
Kukita T; Nomiyama H; Ohmoto Y; Kukita A; Shuto T; Hotokebuchi T; Sugioka Y; Miura R; Iijima T
Lab Invest; 1997 Mar; 76(3):399-406. PubMed ID: 9121122
[TBL] [Abstract][Full Text] [Related]
17. A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy.
Hough RE; Lorigan PC; Poynton C; Newland A; Gupta RK; Foran J; Hancock BW
Int J Oncol; 2003 Feb; 22(2):421-4. PubMed ID: 12527943
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model.
Pender SL; Chance V; Whiting CV; Buckley M; Edwards M; Pettipher R; MacDonald TT
Gut; 2005 Aug; 54(8):1114-20. PubMed ID: 16009684
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
Prendiville J; Crowther D; Thatcher N; Woll PJ; Fox BW; McGown A; Testa N; Stern P; McDermott R; Potter M
Br J Cancer; 1993 Aug; 68(2):418-24. PubMed ID: 8347500
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes.
Lee SC; Brummet ME; Shahabuddin S; Woodworth TG; Georas SN; Leiferman KM; Gilman SC; Stellato C; Gladue RP; Schleimer RP; Beck LA
J Immunol; 2000 Mar; 164(6):3392-401. PubMed ID: 10706735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
